Baird Medical Showcases Innovations in Endocrine Care at 2024 Southern Yue Forum
BDMD 12.30.2024
About Gravity Analytica
Recent News
- 01.22.2025 - Baird Medical Expands into San Francisco, Advancing U.S. Market Growth
- 01.21.2025 - Dr. Emad Kandil Achieves Milestone of 100 Microwave Ablation Cases in Thyroid Care
- 01.17.2025 - Baird Medical Engages with Healthcare Leaders Amid 2025 J.P. Morgan Healthcare Conference
Recent Filings
This distinguished forum, organized by prominent healthcare institutions in
As a sponsor, Baird Medical presented its cutting-edge microwave ablation technology, designed to deliver precise and efficient treatment options for endocrine conditions, including parathyroid diseases. Participants had the opportunity to learn about the company's approach to minimally invasive therapies, aimed at optimizing patient outcomes.
"We are pleased to participate in this highly regarded forum, which reflects our ongoing commitment to supporting medical advancements in endocrine disease management,"said Haimei Wu, Chairwoman of Baird Medical. "Our focus remains on empowering medical professionals with innovative solutions that contribute to improved patient care and clinical outcomes."
The forum provided Baird Medical with the opportunity to engage with key opinion leaders, foster collaborations, and deepen its understanding of evolving clinical needs. The company's participation underscores its commitment to advancing minimally invasive medical technologies and contributing to the broader healthcare community in a responsible and impactful manner.
About Baird MedicalBaird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visithttps://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.
These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.
Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-innovations-in-endocrine-care-at-2024-southern-yue-forum-302340100.html
SOURCE BDMD
Eric Huang, PR Liaison, Baird Medical LLC, Phone: +1 (888) 508-6228, Email: erichuang@bairdmed.com